Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Our researchers and clinicians are involved in clinical and basic science research to enhance our understanding of inflammatory breast cancer, develop more effective diagnostic and treatment options for patients, improve the current survival rate for patients with IBC, and expand prevention strategies for women at risk for this disease.
In addition, through the acquisition of tissue samples from IBC patients, our team is investigating the unique biology of the disease, including its genetic associations. We encourage our patients to participate in our IBC tissue registry, a resource that supports basic science research of IBC, improves the understanding of this disease, and guides treatment.
One focus of our research is to take information "from bench to bedside and back." An example of our success in this avenue is the creation of clinical trial DF/HCC 16-151 (TBCRC 039), a national study for newly-diagnosed triple negative IBC. It is based on evidence from Dana-Farber laboratory scientists, including Kornelia Polyak MD,PhD identified a cellular mechanism that helps IBC cells survive, and identified a drug to stop block this mechanism. This drug, now the focus of the clinical trial for people with triple negative IBC, aims to improve treatment for their disease.
You may also be eligible for other breast cancer clinical trials that include IBC. Talk with your clinician about whether a clinical trial may be right for you.
Search Dana-Farber's clinical trials.
Participating in a clinical trial is a very personal decision, and a choice that is completely yours to make. If it feels right to you, there are several good reasons to participate:
Appointments and Second Opinions